OTC Markets OTCQX - Delayed Quote USD

Medexus Pharmaceuticals Inc. (MEDXF)

2.8000

0.0000

(0.00%)

At close: January 21 at 3:00:00 PM EST

Medexus and British Columbia's Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, Canada

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 15, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with British Columbia's Provincial Health Services Authority (PHSA), a publicly funded health service provider in the Canadian province, for a new approved indication for Trecondyv® (treosulfan for injection) to be listed on the BC Cancer Benefit Drug List and funded through BC Cancer, a part of PHSA that provides a province-wide p

Newsfile 6 days ago

MEDXF
0.00%
Despite the downward trend in earnings at Medexus Pharmaceuticals (TSE:MDP) the stock spikes 16%, bringing one-year gains to 48%

If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly...

Simply Wall St. 27 days ago

MEDXF
0.00%
Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement, Setting Regulatory Milestone Amounts and Payment Schedule

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - December 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company recently entered into a fourth amendment to its February 2021 exclusive license agreement with medac relating to commercialization of treosulfan in the United States.Among other things, the fourth amendment adjusts the unpaid regulatory milestone payments under the US treosulfan agreement. Upon an FDA approval of treosulfan, Medex

Newsfile last month

MEDXF
0.00%
Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 18, 2024) - Earlier in November 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) successfully completed a negotiation process with the pan-Canadian Pharmaceutical Alliance seeking to make Trecondyv® (treosulfan for injection) accessible to publicly funded drug programs and patients in Canada. The pCPA is an independent organization whose membership includes the provincial, territorial, and federal governments.Reaching this

Newsfile 2 months ago

MEDXF
0.00%
Some May Be Optimistic About Medexus Pharmaceuticals' (TSE:MDP) Earnings

Investors were disappointed with the weak earnings posted by Medexus Pharmaceuticals Inc. ( TSE:MDP ). However, our...

Simply Wall St. 2 months ago

MEDXF
0.00%
Should We Be Cautious About Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 7.0%?

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Simply Wall St. 2 months ago

MEDXF
0.00%
Medexus Announces Strong Fiscal Q2 2025 Results

Fiscal Q2 2025 revenue of $26.3 million, net income of $0.1 million, operating income of $1.6 million, and Adjusted EBITDA* of $6.0 millionManagement to host conference call at 8:00 AM Eastern time on Friday, November 8, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's second fiscal quarter ended September 30, ...

Newsfile 2 months ago

MEDXF
0.00%
Medexus Schedules Second Fiscal Quarter 2025 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 29, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, November 8, 2024 to discuss Medexus's results for its second fiscal quarter ended September 30, 2024. Medexus expects to file its financial statements and MD&A after markets close on November 7, 2024.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian ...

Newsfile 2 months ago

MEDXF
0.00%
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 19, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 7, 2024 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors.Detailed voting results for the election of di

Newsfile 4 months ago

MEDXF
0.00%
Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 16, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has extended the review period for the New Drug Application for treosulfan by three months. The FDA has set a new PDUFA target action date of January 30, 2025.The FDA notified medac that the Agency requires additional time ...

Newsfile 4 months ago

MEDXF
0.00%
Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Medexus Pharmaceuticals Inc. ( TSE:MDP ) just released its first-quarter report and things are looking bullish. It was...

Simply Wall St. 5 months ago

MEDXF
0.00%
Medexus Announces Strong Fiscal Q1 2025 Results

Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA* of $6.1 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, August 8, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's first fiscal quarter ended June 30, ...

Newsfile 5 months ago

MEDXF
0.00%
Medexus Schedules First Fiscal Quarter 2025 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August 8, 2024 to discuss Medexus's results for its first fiscal quarter ended June 30, 2024. Medexus expects to file its financial statements and MD&A after markets close on August 7, 2024.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian ...

Newsfile 5 months ago

MEDXF
0.00%
Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024

FDA has Accepted for Review the Treosulfan NDAManagement to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2024 (the company's fiscal Q4 2024 and fiscal year 2024). All dollar ...

Newsfile 6 months ago

MEDXF
0.00%
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2024. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2024.To participate in the call, please dial the following numbers:888-506-0062 ...

Newsfile 7 months ago

MEDXF
0.00%
FDA Accepts for Review Treosulfan NDA Resubmission

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has accepted for review medac's April 2024 resubmission of the New Drug Application for treosulfan. Medexus expects that the FDA will complete its review of the treosulfan NDA and issue a decision by October ...

Newsfile 7 months ago

MEDXF
0.00%
With A Return On Equity Of 20%, Has Medexus Pharmaceuticals Inc.'s (TSE:MDP) Management Done Well?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Simply Wall St. 8 months ago

MEDXF
0.00%
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) and medac, licensor of Medexus's commercialization rights to Metoject®, have elected not to appeal the trial court decision. Medexus and medac initiated the litigation in August 2020 in response to the "at-risk" launch of a generic ...

Newsfile 8 months ago

MEDXF
0.00%
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024.Event: 2024 Bloom Burton & Co. Healthcare Investor ConferenceDate: April 16-17, 2024Location: Toronto, OntarioMedexus Presentation: Wednesday, April 17 at 1:30 PM Eastern timeKen d'Entremont, Medexus's Chief Executive

Newsfile 9 months ago

MEDXF
0.00%
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age group Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that the US Food and Drug Administration (FDA) recently approved Medexus's supplemental Biologics License Application (sBLA) for IXINITY® [coagulation factor IX (recombinant)] for the on-dem

Newsfile 9 months ago

MEDXF
0.00%

Performance Overview

Return	MEDXF	S&P/TSX Composite index
YTD	+21.69%	+2.68%
1-Year	+47.37%	+20.93%
3-Year	+27.85%	+20.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Medexus Pharmaceuticals Inc. (MEDXF)

Medexus and British Columbia's Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, Canada

Despite the downward trend in earnings at Medexus Pharmaceuticals (TSE:MDP) the stock spikes 16%, bringing one-year gains to 48%

Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement, Setting Regulatory Milestone Amounts and Payment Schedule

Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada

Some May Be Optimistic About Medexus Pharmaceuticals' (TSE:MDP) Earnings

Should We Be Cautious About Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 7.0%?

Medexus Announces Strong Fiscal Q2 2025 Results

Medexus Schedules Second Fiscal Quarter 2025 Conference Call

Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors

Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date

Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Medexus Announces Strong Fiscal Q1 2025 Results

Medexus Schedules First Fiscal Quarter 2025 Conference Call

Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024

Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call

FDA Accepts for Review Treosulfan NDA Resubmission

With A Return On Equity Of 20%, Has Medexus Pharmaceuticals Inc.'s (TSE:MDP) Management Done Well?

Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada

Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Performance Overview